Critical Care & Emergencies (all articles)
AHA Scientific Statement: Managing atrial fibrillation in patients with heart failure and reduced ejection fraction.
1 Jul, 2021 | 09:46h | UTCTop Things to Know: Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction
Commentary on Twitter
Pleased to share AHA Scientific statement on ‘Managing AF in pts with HFrEF’ just published @CirculationEP. https://t.co/WRx3QnrxHF Many thanks to the writing group and reviewers for making this excellent guidance document possible @AHAScience @American_Heart @CircAHA #Epeeps pic.twitter.com/PoqqlyA0iA
— Rakesh Gopinath (@drrakeshg1) June 23, 2021
M-A: Simultaneous use of hypertonic saline and IV furosemide for fluid overload – “Benefits of the HSS+Fx over Fx were observed across all examined outcomes in acute decompensated heart failure patients with fluid overload”.
1 Jul, 2021 | 09:41h | UTCSimultaneous Use of Hypertonic Saline and IV Furosemide for Fluid Overload: A Systematic Review and Meta-Analysis – Critical Care Medicine (link to abstract – $ for full-text)
Case Series: Myocarditis following immunization with mRNA COVID-19 vaccines.
30 Jun, 2021 | 10:22h | UTCSee also: Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination – JAMA Cardiology
Editorials: Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines AND Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The Vaccine Safety Surveillance System Is Working
Commentary: More Evidence Links Myocarditis to mRNA COVID-19 Vaccines – TCTMD
Commentary on Twitter
2 new reports of myocarditis after mRNA vaccination documenting its rare occurrence
23 males serving in the military among 2.8 million doses givenhttps://t.co/yPbYxkuSHi
4 cases in North Carolina, including a 70-year-old womanhttps://t.co/Iwj2Hx6O2U@JAMACardio pic.twitter.com/fv2JoOFAyt— Eric Topol (@EricTopol) June 29, 2021
Covid: Masks upgrade cuts infection risk, research finds.
30 Jun, 2021 | 10:16h | UTCCovid: Masks upgrade cuts infection risk, research finds – BBC
Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome.
30 Jun, 2021 | 10:13h | UTC
Consensus Statement: The role of lung ultrasound in COVID-19 disease.
30 Jun, 2021 | 10:12h | UTCThe role of lung ultrasound in COVID-19 disease – Insights into Imaging
M-A: The utility of the rapid shallow breathing index in predicting successful extubation – “As a stand-alone test, the RSBI has moderate sensitivity and poor specificity for predicting extubation success”.
30 Jun, 2021 | 10:07h | UTCThe Utility of the Rapid Shallow Breathing Index in Predicting Successful Extubation: A Systematic Review and Meta-analysis – CHEST (link to abstract – $ for full-text)
Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.
29 Jun, 2021 | 10:07h | UTCThrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine – Annals of Internal Medicine
Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.
29 Jun, 2021 | 10:00h | UTC
EBM Analysis | Does tranexamic acid work for everything? For anything?
29 Jun, 2021 | 09:53h | UTCDoes TXA work for everything? For anything? – First10EM
IDSA Updated Covid-19 Guidance: Co-Infection and Antimicrobial Stewardship – “bacterial coinfections with SARS-CoV-2 infection are relatively infrequent (likely occurring in less than 10% of hospitalized COVID-19 patients)”.
28 Jun, 2021 | 09:51h | UTCCo-Infection and Antimicrobial Stewardship – Infectious Diseases Society of America
Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department.
28 Jun, 2021 | 09:43h | UTC
AASLD Guideline: Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease.
28 Jun, 2021 | 09:33h | UTC
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.
25 Jun, 2021 | 10:37h | UTC
Commentary on Twitter
#COVID19 Associated Pulmonary Aspergillosis
?increasing, associated with excess mortality
?complex: colonization + tissue/angio-invasion
?diagnose? bronchoscopy/BAL
?antifungals recommended
?consider discontinuating/tapering steroids in no respondershttps://t.co/HhS6wUfibn pic.twitter.com/CJwE3CEXxn— Intens Care Med (@yourICM) June 23, 2021
IDSA 2021 focused update guidelines on the management of Clostridioides difficile infection in adults.
25 Jun, 2021 | 10:17h | UTCNews release: IDSA And SHEA Release New Guidelines for Managing Clostridium Difficile Infection – Infectious Diseases Society of America
Commentary on Twitter
????Clinical Practice Guideline @IDSAInfo @SHEA_Epi 2021 Focused Update Guidelines on Management of CDI in Adults
Major update?:for patients with an initial CDI episode, guidelines suggest using fidaxomicin rather than a standard course of vancomycin https://t.co/2iqcoTHqLL pic.twitter.com/2uzZamvkkr— Antibiotic Steward ???Bassam Ghanem (@ABsteward) June 24, 2021
Perspective | Delta variant triggers dangerous new phase in the pandemic.
24 Jun, 2021 | 10:43h | UTCDelta variant triggers dangerous new phase in the pandemic – Science
CDC: mRNA vaccines are likely linked to cases of myocarditis and pericarditis – 1,226 cases of myocarditis or pericarditis have been reported mostly in people under 30.
24 Jun, 2021 | 09:51h | UTCSee also: Experts: mRNA COVID-19 vaccines likely tied to heart inflammation – CIDRAP
Related: Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination. AND Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination. AND Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination. AND CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Review | My Treatment Approach to Clostridioides difficile Infection.
24 Jun, 2021 | 09:47h | UTCMy Treatment Approach to Clostridioides difficile Infection – Mayo Clinic Proceedings
[News release – not published yet] COVID-19 outpatient thrombosis prevention trial ends early – “Results suggest that not treating certain symptomatic but stable outpatients with anticoagulant or antiplatelet therapy may be the best course of action”.
23 Jun, 2021 | 10:32h | UTCCommentary: Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b – TCTMD
Interactive Infographic | Interpreting a lateral flow SARS-CoV-2 antigen test – “This calculator demonstrates how interpreting a covid-19 lateral flow device (LFD) result varies according to the pre-test probability, and the sensitivity and specificity of the LFD used”.
23 Jun, 2021 | 10:29h | UTCInterpreting a lateral flow SARS-CoV-2 antigen test – The BMJ
Laboratory testing for suspected COVID-19 vaccine–induced (immune) thrombotic thrombocytopenia.
23 Jun, 2021 | 10:25h | UTC
Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.
22 Jun, 2021 | 10:08h | UTCIvermectin is the new hydroxychloroquine, take 2 – Science-Based Medicine
Related: [Preprint] Meta-analysis of RCT: Ivermectin for the treatment of COVID-19 – no effect on all-cause mortality, length of stay, or viral clearance AND M-A: Prophylaxis against Covid-19: 1 – no benefit from Hydroxychloroquine; 2 – as studies on ivermectin so far have been small, it remains very uncertain whether ivermectin reduces SARS-CoV-2 infection AND Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials AND EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials AND FDA: Why you should not use Ivermectin to treat or prevent COVID-19 AND RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19 AND NIH Guideline Statement: “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19” AND Video (5min): Ivermectin for COVID-19 | A Doctor Explains
Perspective | COVID-19: The rise and rise of Delta.
22 Jun, 2021 | 10:10h | UTCCOVID-19: The rise and rise of Delta – Sciblogs
Case report: Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection.
22 Jun, 2021 | 10:04h | UTC
M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19.
21 Jun, 2021 | 08:45h | UTC